5129 6 archive 3 disk0/00/00/51/29 2026-03-24 11:30:41 2026-03-24 11:31:46 2026-03-24 11:30:41 data_collection show Johnson Sarah FALSE Whittaker Elizabeth FALSE Seddon James FALSE Kampmann Beate 0000-0002-6546-4709 TRUE 252ec2b3d7e2868ae72dc36a9af348ae Payne Helen FALSE London School of Hygiene & Tropical Medicine, London, United Kingdom ITCR Chemoprevention Clinical trials Cluster trials Malaria Medical and health sciences Data for 75 participants (children and adolescents) who had been exposed to a household TB contact. They had subsequently been categorised as having active TB disease, LTBI (Mtb sensitisation), or no evidence of TB. CMV seropositivity and CMV IgG levels were obtained for these patients. Seasonal Malaria Chemoprevention (SMC) currently targets children below 5 years (< 5 yr). It is unclear what the impact of extending SMC to a wider age range will be. We conducted a cluster-randomized trial in Saponé (Burkina Faso) with three study arms: 1) Programmatic SMC-control arm: SMC in children < 5 years; 2) SMC in children < 5 years, with directly observed treatment (DOTu5); 3) SMC in children < 10 years with DOT (DOTu10). The trial involved 61 (programmatic SMC) and 62 (each DOT arms) clusters of 3 compounds (i.e., 183-186 compounds per arm). The primary endpoint was P. falciparum parasite prevalence at the end of the transmission season; secondary endpoints included clinical malaria incidence, drug plasma levels, and gametocyte prevalence. This trial is complete and is registered with ClinicalTrials.gov, NCT05878366. 2025-11-25 published Dryad Dataset Study authors MeasurementsAndTests.Physical none Wellcome Trust NIHR Imperial Biomedical Research Centre Dataset Quantitative RSRO_P67869 en https://doi.org/10.5061/dryad.gxd2547wv dataresource https://researchonline.lshtm.ac.uk/id/eprint/4679204 Wellcome Trust RSRO_P67869 https://doi.org/10.13039/100010269 NIHR Imperial Biomedical Research Centre SRF-2009-02-07 https://doi.org/10.13039/501100013342 2025-11-25